135 related articles for article (PubMed ID: 38099976)
1. Survival outcomes of patients with stage III colorectal cancer aged ≥ 80 years who underwent curative resection: the HiSCO-04 prospective cohort study.
Mochizuki T; Shimomura M; Nakahara M; Adachi T; Ikeda S; Saito Y; Shimizu Y; Kochi M; Ishizaki Y; Yoshimitsu M; Takakura Y; Shimizu W; Sumitani D; Kodama S; Fujimori M; Oheda M; Kobayashi H; Akabane S; Yano T; Ohdan H
Int J Clin Oncol; 2024 Feb; 29(2):159-168. PubMed ID: 38099976
[TBL] [Abstract][Full Text] [Related]
2. A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Okuda H; Shimomura M; Ikeda S; Nakahara M; Miguchi M; Ishizaki Y; Saitoh Y; Toyota K; Sumitani D; Shimizu Y; Takakura Y; Shimizu W; Yoshimitsu M; Kodama S; Fujimori M; Oheda M; Kobayashi H; Ohdan H;
Cancer Chemother Pharmacol; 2023 Apr; 91(4):317-324. PubMed ID: 36947210
[TBL] [Abstract][Full Text] [Related]
3. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Yu YL; Tseng WK; Liao CK; Yeh CY; Chen HH; Liu YH; Liaw YW; Fan CW
BMC Cancer; 2023 Sep; 23(1):900. PubMed ID: 37749535
[TBL] [Abstract][Full Text] [Related]
4. Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Ogata Y; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Sakamoto J; Kusano M; Hyodo I; Taguri M; Morita S
BMC Cancer; 2022 Feb; 22(1):170. PubMed ID: 35168560
[TBL] [Abstract][Full Text] [Related]
5. Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
Chen TC; Jeng YM; Liang JT
J Formos Med Assoc; 2021 May; 120(5):1194-1201. PubMed ID: 33023787
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases.
Kokudo T; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Ishihara S; Makuuchi M; Kokudo N; Hasegawa K
Surgery; 2021 Oct; 170(4):1151-1154. PubMed ID: 34030885
[TBL] [Abstract][Full Text] [Related]
7. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
[TBL] [Abstract][Full Text] [Related]
10. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
[TBL] [Abstract][Full Text] [Related]
13. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Ohwada S; Kawate S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kawashima Y; Nakajima T; Morishita Y;
Dis Colon Rectum; 2003 Aug; 46(8):1060-8. PubMed ID: 12907900
[TBL] [Abstract][Full Text] [Related]
15. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Ogata Y; Matono K; Sasatomi T; Ishibashi N; Ohkita A; Mizobe T; Ogo S; Ikeda S; Ozasa H; Shirouzu K
Cancer Chemother Pharmacol; 2006 May; 57(5):577-83. PubMed ID: 16133529
[TBL] [Abstract][Full Text] [Related]
16. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
17. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
[TBL] [Abstract][Full Text] [Related]
18. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
20. [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Qiu MZ; Teng KY; Ruan DY; Li YH; Chen XQ; Pan ZZ; He YJ; Wan DS; Xu RH
Ai Zheng; 2009 Jul; 28(7):743-8. PubMed ID: 19624903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
